Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2620 • 2012 ACR/ARHP Annual Meeting
Randomized, Double-Blind, Placebo-Controlled Studies of P140 Peptide in Mannitol (Lupuzor) and Trehalose (Forigerimod) in Patients with SLE
Robert Zimmer¹, Daniel J. Wallace² and Sylviane Muller³, ¹ImmuPharma France, Mulhouse, France, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Institut de Biologie Moléculaire et Cellulaire, CNRS, Strasbourg, France
Background/Purpose: Advances in the understanding of autoimmune diseases pathogenesis have led to the development of peptide-based therapies that aim to potentially reinstate tolerance to self…
Abstract Number: 984 • 2012 ACR/ARHP Annual Meeting
Association of Elevated C5a Levels, but Not the Presence of Anti-Cfh IgG Autoantibodies, with the Deletion of CFHR3 and CFHR1 in SLE
Jian Zhao¹, Seema Kamble¹, Yun Deng¹, Magdangal Erika¹, Daisuke Sakurai², Rongqun Li², Weiling Chen², Jennifer M. Grossman³, Bevra H. Hahn⁴ and Betty P. Tsao⁵, ¹Division of Rheumatology, Department of Medicine,, Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ²Division of Rheumatology, Department of Medicine, Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ³Div of Rheumatology, Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ⁴Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Medicine/Rheumatology, Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA
Background/Purpose: We previously reported association of the deletion of complement regulator factor H related CFHR3 and CFHR1 genes (CFHR3-1Δ), rather than CFH exonic SNPs, with…
Abstract Number: 639 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Epratuzumab in an Open-Label Extension Study (SL0006)
K. Hobbs¹, D.J. Wallace², V. Strand³, K. Kalunian⁴, B. Kilgallen⁵, S. Bongardt⁶, W.A. Wegener⁷ and D.M. Goldenberg⁷, ¹Denver Arthritis Clinic, Denver, CO, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Biopharmaceutical Consultant, Portola Valley, CA, ⁴Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Brussels, Belgium, ⁷Immunomedics Inc, Morris Plains, NJ
Background/Purpose: Epratuzumab, a monoclonal antibody targeting CD22, is in development for the treatment of systemic lupus erythematosus (SLE). Two randomized, double-blind trials (ALLEVIATE 1 and…
Abstract Number: 2283 • 2012 ACR/ARHP Annual Meeting
Preferential Association of Complement Receptor 2 Variants with Anti-dsDNA Autoantibodies in Systemic Lupus Erythematosus
Brendan M. Giles¹, Jian Zhao², Kara M. Lough¹, Patrick M. Gaffney on behalf of LLAS2³, Marta E. Alarcon-Riquelme on behalf of BIOLUPUS⁴, Elizabeth E. Brown on behalf of PROFILE⁵, Lindsey A. Criswell⁶, Gary S. Gilkeson⁷, Chaim O. Jacob⁸, Judith A. James⁹, Joan T. Merrill¹⁰, Kathy L. Moser¹¹, Timothy B. Niewold¹², R. Hal Scofield¹³, Timothy J. Vyse¹⁴, John B. Harley¹⁵, Kenneth M. Kaufman¹⁶, Jennifer A. Kelly¹¹, Carl D. Langefeld¹⁷, Jeffrey C. Edberg¹⁸, Robert P. Kimberly¹⁹, Daniela Ulgiati²⁰, Betty P. Tsao²¹ and Susan A. Boackle²², ¹University of Colorado School of Medicine, Aurora, CO, ²Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ³Arthritis and Immunology Prog, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁷Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ⁹Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ¹³Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴Division of Genetics and Molecular Medicine and Division of Immunology, Infection and Inflammatory Disease, King's College London, London, United Kingdom, ¹⁵Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁷Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, ¹⁸Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ¹⁹Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²⁰University of Western Australia, Perth, Western Australia, Australia, ²¹Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA, ²²Medicine/Rheumatology, University of Colorado School of Medicine, Aurora, CO
Background/Purpose: Complement receptor 2 (CR2/CD21) is primarily expressed on B cells and follicular dendritic cells (FDC) and is required for normal humoral immune responses. We…
Abstract Number: 992 • 2012 ACR/ARHP Annual Meeting
Functional Genomics of the Human ITGAM Locus
Yebin Zhou¹, Dan C. Bullard¹, Alexander Szalai², Jianming Wu³ and Jeffrey C. Edberg⁴, ¹Genetics, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology, University of alabama at birmingham, Birmingham, AL, ³Veterinary and Biomedical Science, Medicine, University of minnesota, St. Paul, MN, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: ITGAM encodes CD11b, the αM subunit of the Mac-1 -αMβ2 integrin. Mac-1 has many functions on leukocytes including its role as an adhesion molecule…
Abstract Number: 613 • 2012 ACR/ARHP Annual Meeting
Serum Level of Syndecan-1 Is Associated with Disease Activity in Patients with Systemic Lupus Erythematosus
In-Woon Baek¹, Ki-Jo Kim², Ji-Young Kim³, Su-Jung Park³, Chong-Hyeun Yoon⁴, Wan-Uk Kim⁵ and Chul Soo Cho⁶, ¹Internal medicine, Catholic University of Korea, Callege of Medicine, Seoul, South Korea, ²Internal Medicine, College of Medicine, Catholic University of Korea, Seoul, South Korea, ³Internal Medicine, Research Institute of Bone & Joint Diseases, Catholic University of Korea, Seoul, South Korea, ⁴Internal Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Uijeongbu, South Korea, ⁵Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶St Marys Hospital, Seoul, South Korea
Background/Purpose: Syndecan-1(SDC1), a transmemebrane heparan-sulfate glycoprotein, is predominantly expressed by plasma cells and is a receptor for a proliferation-inducing ligand (APRIL). SDC-1 is readily shed…
Abstract Number: 2245 • 2012 ACR/ARHP Annual Meeting
Vitamin D Deficiency Is Associated with, but Does Not Predict, Change in hsCRP in Systemic Lupus Erythematosus (SLE)
Adnan Kiani, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: In the general population the cardioprotective effects of vitamin D are thought to be due to modulation of inflammatory cytokines. However, the effects of…
Abstract Number: 934 • 2012 ACR/ARHP Annual Meeting
Direct Medical Cost Associated with Organ System Involvement in a Commercially Insured Population with Systemic Lupus Erythematosus in the United States
Alan Oglesby¹, Emily Durden², Siva Narayanan³, Paul Juneau⁴ and Kathleen L. Wilson⁵, ¹GlaxoSmithKline, Research Triangle Park, NC, ²Thomson Reuters, Austin, TX, ³Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD, ⁴Truven Health Analytics, Washington, DC, ⁵Thomson Reuters Healthcare, Cambridge, MA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs including the heart, lungs, kidneys, as well as the joints and…
Abstract Number: 619 • 2012 ACR/ARHP Annual Meeting
Elevated Plasma Levels of CXCL2 and CXCL10 Have Distinct Predictive Value in Systemic Lupus Erythematosus
Felipe Andrade¹, Ehtisham Akhter², Hong Fang³ and Michelle Petri³, ¹Division of Rheumatology, Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Serum levels of chemokines have been previously used as downstream markers of the interferon (IFN) pathway in SLE. CXCL2 (GROB) and CXCL10 (IP-10) have…
Abstract Number: 2247 • 2012 ACR/ARHP Annual Meeting
The First Report of Desensitization to Trimethoprim/Sulfamethoxazole in Patients with Systemic Lupus Eryhtematosus
Yasuhiro Suyama¹, Mitsumasa Kishimoto², Hiroto Nakano³, Ken-ichi Yamaguchi¹, Hisanori Shimizu⁴, Ryo Rokutanda⁴, Chisun Min², Yuri Ohara⁴, Yoichiro Haji², Kazuo Matsui⁵, Akira Takeda⁶, Yukio Matsui⁷ and Masato Okada⁷, ¹Division of Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ²Division of Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ³Department of Rheumatology, Kameda Medical Center, Kamogawa City, Japan, ⁴Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁵Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ⁶Division of Clinical Immunology & Rheumatology, International University of Health and Welfare Hospital, Nasu-shiobara, Japan, ⁷Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan
Background/Purpose: Trimethoprin-sulfamethoxazole (TMP/SMX) is the most effective and widely used prophylactic medication in immunocompromised patients. Some diseases are well-known to cause allergic reactions including human…
Abstract Number: 935 • 2012 ACR/ARHP Annual Meeting
Primary Care Preventive Services in Patients with Systemic Lupus Erythematosus Compared to Others in Their Community
Cristina Drenkard¹, Kimberley Rask², Gaobin Bao³, Gnanesh Patel⁴, Suparna Bagchi⁵ and S. Sam Lim⁶, ¹Medicine, Div Rheumatology, Emory University, Atlanta, GA, ²Health Policy and Management, Emory University, Atlanta, GA, ³Medicine, Emory University, Atlanta, GA, ⁴Emory University, Atlanta, GA, ⁵Georgia Department of Public Health, Atlanta, GA, ⁶Emory University School of Medicine, Division of Rheumatology, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic illness frequently complicated by infections, cardiovascular disease (CVD) and cancer. Primary care preventive services (PCS) are recommended…
Abstract Number: 624 • 2012 ACR/ARHP Annual Meeting
Excess Health Care Utilization Prior to Diagnosis of Systemic Lupus Erythematosus in England
Amy Steffey¹, Trung N. Tran¹, Jie Li¹ and Herve Caspard², ¹Epidemiology, Clinical Development, MedImmune, Gaithersburg, MD, ²Epidemiology, Clinical Development, MedImmune LLC, Gaithersburg, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic auto-immune disease resulting in significant excess morbidity and health care utilization. Since time of disease onset is…
Abstract Number: 2252 • 2012 ACR/ARHP Annual Meeting
Epratuzumab-Treated Systemic Lupus Erythematosus Patients Report Improvements in Health-Related Quality of Life: Final Results from an Open-Label Extension Study (SL0006)
V. Strand¹, K. Hobbs², D.J. Wallace³, K. Kalunian⁴, B. Kilgallen⁵, E. Nikaï⁶, W.A. Wegener⁷ and D.M. Goldenberg⁸, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Denver Arthritis Clinic, Denver, CO, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴UCSD School of Medicine, La Jolla, CA, ⁵UCB Pharma, Smyrna, GA, ⁶UCB Pharma, Brussels, Belgium, ⁷Immunomedics Inc, Morris Plains, NJ, ⁸Centre for Molecular Medicine and Immunology, Morris Plains, NJ
Background/Purpose: Epratuzumab, a monoclonal antibody targeting CD22, is in development for the treatment of systemic lupus erythematosus (SLE). Two randomized controlled trials (RCTs): ALLEVIATE 1…
Abstract Number: 937 • 2012 ACR/ARHP Annual Meeting
Changes in Ten Year Survival Among SLE Patients At an Academic Center in North America (1970-2011)
Joseph F. Merola¹, Bonnie L. Bermas², Bing Lu¹, Peter Hsun Tsao¹, Tabatha Norton¹, Christina Iversen¹, Elizabeth W. Karlson², Peter H. Schur¹ and Karen H. Costenbader¹, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Data from other large SLE cohorts have suggested improving survival among SLE patients in recent years with protective effects from antimalarial use and less…
Abstract Number: 625 • 2012 ACR/ARHP Annual Meeting
Control of Hypertension and Hypercholesterolemia Is Not Associated with a Decreased Rate of Atherosclerotic Vascular Events in Patients with Systemic Lupus Erythematosus
Joanna Ueng¹, D. D. Gladman², Dominique Ibanez³ and Murray B. Urowitz³, ¹Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ²Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology. It has been shown that patients with SLE are at a higher…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].